openPR Logo
Press release

Viral Conjunctivitis Drugs Market - Global Industry Insights, Trends, Outlook and Opportunity Analysis 2017-2025

02-17-2018 09:26 AM CET | Health & Medicine

Press release from: Pharmaceutical Report By CMI

Viral Conjunctivitis Drugs Market - Global Industry Insights,

Viral conjunctivitis is an inflammation of the conjunctiva, which is a thin outermost layer of the sclera and inner layer of eyelid. Viral conjunctiva is caused due to infections from virus such as adenovirus, herpes simplex virus, varicella zoster virus, picornavirus, poxvirus, and human immunodeficiency virus. It is also called as Pinkeye disease. Viral conjunctivitis is characterized by the reddish eye, watery discharge from eye, and itching/irritation. Persistent conjunctivitis from virus may lead to corneal keratitis. Treatment for viral conjunctivitis may be symptomatic or virus specific.

Treatment can include artificial tear drops to lower the dryness and irritation from infection, vasoconstrictors to reduce eye redness, decongestants to reduce the swelling, and antihistamines to reduce itching. Treatments usually are continued for one to two weeks, depending on the severity of the infection. Anti-viral therapy is utilized to treat infections from herpes simplex and varicella zoster virus.

Request a sample copy of this report:

New drugs development in the U.S. to propel growth of the viral conjunctivitis market

According to study published in the journal Ophthalmology in December 2017, approximately 80% of conjunctivitis cases in the U.S. are associated with viral conjunctivitis. According to study published in Review of Ophthalmology in January 2017, around 15 per 1000 population in the U.S. suffer from viral conjunctivitis. As per a study in Review of Optometry in 2016, an estimated 20,000 new cases, 48,000 cases of recurrences, and prevalence of 4,00,000 cases of herpes simplex keratitis were reported every year in U.S. Considering this facts, U.S. is expected to dominate the viral conjunctivitis drugs market. Also, increasing investment for development of new drugs to treat the viral conjunctivitis are further expected to propel the viral conjunctivitis drugs market growth. For instance, APD-209 is a drug candidate from Adenovir Pharma AB to treat epidemic keratoconjunctivitis from adenovirus, which has completed the phase 2 clinical studies in 2016. There is also increased awareness amongst patients about approaching the ophthalmologist to treat viral conjunctivitis.

However, there is no direct anti-viral treatment available yet for conjunctivitis, which if available may open new opportunity in viral conjunctivitis drugs market. To treat viral conjunctivitis often it becomes difficult to clinically differentiate the viral conjunctivitis from the bacterial conjunctivitis which leads to miss diagnosis. Many physicians at primary care centers prescribe antibiotic to treat viral conjunctivitis due to miss diagnosis and this chain of events limits the expansion of viral conjunctivitis drugs market. According to 2017 study in Ophthalmology, an estimated 83% patients of acute conjunctivitis visited primary care centers instead of ophthalmologist, which leads to overlap of diagnosis and treatment of viral conjunctivitis in turn restraining market growth.

Viral Conjunctivitis Drugs Market Taxonomy

On the basis of drug class:

Artificial tears
Anti-Viral drugs

On the basis of the distribution channel:

Hospital Pharmacy
Retail Pharmacy

Key players operating in the viral conjunctivitis drugs market include Bausch & Lomb, Allergan plc, Shire plc, NicOx S.A, NovaBay Pharmaceuticals, Inc., NanoViricides, Inc., Novartis International AG, Adenovir Pharma AB, Panoptes Pharma GES.M.B.H., Akorn Pharmaceuticals, and Quidel Corporation. Market players are investing in research to development of novel therapies to treat viral conjunctivitis.

Click here to know more about this report:

NiCox S.A. in March 2017, received the FDA approval for its ZERVIATE1 (cetirizine ophthalmic solution 0.24%) as New Drug Application (NDA), which is the first antihistaminic topical ocular formulation for the treatment of itching due to allergic conjunctivitis. Company is looking to commercialize the product in the U.S. through partnership. In 2015, Shire plc announced acquisition of Foresight Biotherapeutics for US$ 300 million. Foresight Biotherapeutics has experimental eye drop FST-100 in its pipeline, which is a combination of 0.6% povidone iodine and 0.1% dexamethasone to treat both viral and bacterial conjunctivitis. This acquisition would add growth to Shire plc’s ophthalmic portfolio.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Visit our news Website:

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Viral Conjunctivitis Drugs Market - Global Industry Insights, Trends, Outlook and Opportunity Analysis 2017-2025 here

News-ID: 947084 • Views: 267

More Releases from Pharmaceutical Report By CMI

Rising prevalence of diabetes is a major factor driving growth of the diabetic f …
Diabetic foot ulcers is a common condition in diabetic patients. It is a disabling disorder, which might lead to amputation of the leg. Mortality due to diabetic foot ulcers is high and chances of recurrence of cured foot ulcers is also high and this in turn leads to increasing demand for proper treatment of diabetic foot ulcers. Diabetic foot ulcer is caused due to neuropathic and vascular changes in the
Glucagon-Like Peptide-1 (Glp-1) Analogs Market Global Industry Insights, Trends, …
Glucagon-like peptide-1 (GLP-1) analogs also known as incretin mimetics are class of drugs indicated for type-2 diabetes mellitus to lower the blood sugar level. GLP-1 analogs prevents the breakdown of GLP-1, thereby enhancing the glucose depended insulin release, suppresses the glucagon release (which reduces hepatic glucose output), and reduces gastric emptying rate (resulting in weight loss from reduced appetite). GLP-1 analogs do not cause hypoglycemia like other class of anti-diabetic
Multiple Sclerosis Therapeutics Market to Surpass US$ 24.4 Billion by 2025
Increasing prevalence of multiple sclerosis to augment market growth Multiple sclerosis is a widespread disabling neurological condition, mostly diagnosed in people in the age group 20–50 years. According to the Multiple Sclerosis Foundation, 2017, this autoimmune condition affects 2.5 million people with the global incidence of around 7 cases per 100,000 people per year. The study also states that prevalence rates varies between ethnic and geographical latitudes, ranging from 50 to
Diabetic Foot Ulcers Treatment Market to Surpass US$ 9.49 Billion Threshold by 2 …
Diabetic foot ulcers is a common condition in diabetic patients. It is a disabling disorder, which might lead to amputation of the leg. Mortality due to diabetic foot ulcers is high and chances of recurrence of cured foot ulcers is also high and this in turn leads to increasing demand for proper treatment of diabetic foot ulcers. Diabetic foot ulcer is caused due to neuropathic and vascular changes in the

All 5 Releases

More Releases for Viral

Viral Conjunctivitis Market- Pipeline Review, H1 2020
A new research document is added in HTF MI database of 50 pages, titled as 'Viral Conjunctivitis - Pipeline Review, H1 2020' with detailed analysis, Competitive landscape, forecast and strategies. The study covers geographic analysis that includes regions like North America, Europe or Asia and important players/vendors such as Adenovir Pharma AB, Invirsa Inc, IVIEW Therapeutics Inc, NanoViricides Inc, Okogen Inc, Panoptes Pharma GesmbH, Starpharma Holdings Ltd, TGV-Inhalonix Inc. The
Viral Vaccines Market : Challenges and Opportunities Against Viral Diseases
Vaccines are biotic compositions. They are basically formulated from living beings that increase the resistance against a specific illness. Vaccinations that help in avoiding the occurrence of specific diseases are known as prophylactic vaccines and in other instance, the vaccines that are helpful in treating the disease are called therapeutic vaccines. A vaccine is generally produced by using a weakened or murdered type of the sickness causing microorganism. The agent
Viral Inactivation - Global Market Outlook (2017-2023)
The latest industry research report on Viral Inactivation by MRC provides a thorough analysis of the global Viral Inactivation market. The report scrutinizes the market by different segments including regions, applications, competitive landscape, etc. over the predicted time frame. This report provides 360 Degree perspective of the Viral Inactivation industry with an all-inclusive discussion of definitions, classifications, and market players in the industry chain structure. It features qualitative and quantitative
Global Viral Molecular Diagnostics Market
The Viral Molecular Diagnostics Market reportprovides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies. Molecular diagnostics refers to a technique used to detect and identify the presence of genetic material or proteins associated with a specific health condition or disease. Viral molecular diagnostic helps in
Fzillion Goes 'VIRAL' with itsLatest Additions
Both Quality and Quantity - How Fzillion has made it possible The world is known online retailer Fzillion is now showcasing the very best of the fashion world. Just recently the store has added the newest men and kids apparel to its extensive collection. Fzillion gives you a wide range of items, ranging from high prices to low prices, from winger collections to summer collections, from everyday casual wear to the
Detecting and Preventing Viral Contamination of Food
Foodborne viral outbreaks are ever present in the media spotlight. The European Food Safety Authority (EFSA) reported that viral agents were responsible for 11.9% of the foodborne outbreaks in the European Union (EU) during 2007, coming second only to Salmonella as the most common causation agent group. Undetected food contamination Foodborne viral infections often go undetected and differ from bacterial infections in that, once present in food, viruses will neither alter the